Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case of cross-reactivities, CAR T cells may also attack...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Bachmann, Dominik, Aliperta, Roberta, Bergmann, Ralf, Feldmann, Anja, Koristka, Stefanie, Arndt, Claudia, Loff, Simon, Welzel, Petra, Albert, Susann, Kegler, Alexandra, Ehninger, Armin, Cartellieri, Marc, Ehninger, Gerhard, Bornhäuser, Martin, von Bonin, Malte, Werner, Carsten, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800918/
https://ncbi.nlm.nih.gov/pubmed/29484126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23556
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares